Human enterovirus 68 (EVD68) is a primary causative agent for respiratory illness worldwide. Until now, there has been no available medication for treating EVD68-related diseases. Rheum emodin, artemisinin, astragaloside, pseudolaric acid B, oridonin, and erianin are natural extracts from Chinese herbs that have traditionally been used for the treatment and prevention of epidemic diseases. Our results showed that pseudolaric acid B protected cells from EVD68-induced cytopathic effects and decreased viral production. However, the same effects were not observed with rheum emodin, astragaloside, or artemisinin. Pseudolaric acid B inhibited EVD68 production by manipulating the host cell cycle in G2/M phase. Further, either oridonin or erianin related G2/M arrest also inhibited viral production. Due to inducing G2/M phase arrest, pseudolaric acid B, oridonin, and erianin might be good candidates for inhibiting EVD68 production, and Chinese herbs with natural compounds inducing G2/M arrest should be considered for the treatment of EVD68-related diseases. KEYWORDS enterovirus D68 (EVD68), G2/M arrest, natural compounds, viral production
| INTRODUCTION
Human enterovirus 68 (EVD68) is an emerging pathogen that can cause severe respiratory disease and is associated with cases of paralysis, especially among children. It was first isolated from samples obtained in California in 1962 from four children with pneumonia and bronchiolitis (Schieble, Fox, & Lennette, 1967) . During the past 10 years, EVD68 infection outbreaks have been reported in Italy, the United States, Germany, China, and several other countries (Esposito et al., 2015; Farrell et al., 2015; Reiche et al., 2015; Zhang et al., 2015) , with a record number of confirmed cases in 2014 (http://www.cdc.gov/non-polio-enterovirus/about/ev-d68. html). Unfortunately, no vaccines for prevention or medications for treatment are currently available.
In a previous study, we demonstrate that the EVD68 virus manipulates cell cycle arrest in the G0/G1 phase for viral replication . This indicates the possibility of developing cell cyclemodifying agents (especially those that induce S or G2/M phase arrest) as a novel strategy for treating EVD68-related diseases. Normally, the cell cycle is controlled by the binding of cyclin-dependent kinase (CDK) to the corresponding cyclin regulatory subunits, which are tightly regulated temporally. The G1 phase cyclins, cyclin D and cyclin E, associate predominantly with CDK 4/CDK 6 and CDK 2, respectively, to promote G1 progression and S-phase entry (Sherr, *These authors contributed equally to this work. 1994). Both cyclin A and cyclin E then combine, mainly with CDK 2, to promote S-phase progression (Lundberg & Weinberg, 1998) . Subsequently, CDK 1/cyclin B regulate mitotic entry and mitotic exit Yu, Wang, et al., 2008) . P21 and P27 are the downstream proteins of P53, and they bind directly with different cyclin-CDK complexes and inhibit their kinase activity thereby causing cell cycle arrest (Schafer, 1998; Schwartz & Rotter, 1998; Taylor & Stark, 2001 ). And it is confirmed that some viruses regulate cell cycle progression by manipulating cyclin and CDK progression (Caffarelli, Fehr, & Yu, 2013; Adeyemi & Pintel, 2014) , therefore, through regulating host cell cycle to inhibit viral production is feasible strategy.
Natural products have played pivotal roles in the drug discovery and development process. It has been noted that natural products embody more "privileged structures" (DeSimone, Currie, Mitchell, Darrow, & Pippin, 2004) than purely synthetic chemical libraries and possess the characteristics and therapeutic effects of Chinese herbs (Breinbauer, Vetter, & Waldmann, 2002) . Natural product-based drug discovery research programs represent important avenues for drug development (Mann, 2002) , including antiviral drugs (Si et al., 2005; Si et al., 2007; Lee et al., 2017; Ryu et al., 2017; Zhang et al., 2017) .
For example, rheum emodin (1,3,8-trihydroxy-6-methylanthraquinone) is an active ingredient sourced from herbs belonging to the genera rheum, polygonum, rhamnus, and senna. Extracts from these herbs have been used for the treatment of epidemic-prone diseases (Huang, Lu, Shen, Chung, & Ong, 2007) . Emodin inhibits the replication of severe acute respiratory syndrome virus (Schwarz, Wang, Yu, Sun, & Schwarz, 2011) , hepatitis B (Shuangsuo et al., 2006) , and herpes simplex viruses (Xiong et al., 2010) . Artemisinin, a drug obtained from the plant Artemisia annua, is recommended by the World Health Organization for the treatment of infections such as drug-resistant Plasmodium falciparum strains, cerebral malaria, and malaria in children (Yeung, Pongtavornpinyo, Hastings, Mills, & White, 2004) . A major saponin of this herb, astragaloside, has anticancer, antifatigue, anti-Coxsackie B virus, and anti-inflammatory effects (Chen et al., 2011) . Pseudolaric acid B, which is a diterpene acid isolated from the roots and trunk bark of Pseudolarix kaempferi Grord (Pinaceae), has antifungal (Li, Clark, & Hufford, 1995) and antitumor activities (Yu et al., 2007; Yu et al., 2013; Yu et al., 2016; Yu et al., 2017; Yu, Wang, et al., 2008) . Oridonin, an active diterpenoid isolated from Rabdosia rubescens, has antitumor Ye et al., 2012) and anti-inflammatory effects. Erianin, a natural product derived from Dendrobium chrysotoxum, has exhibited potential antitumor activity in various malignancies . However, to date, the potential anti-EVD68 activity of these natural compounds has not been well studied.
In this study, we elucidated the anti-EVD68 activity of the natural active components of rheum emodin, astragaloside, artemisinin, pseudolaric acid B, oridonin, and erianin. We observed that pseudolaric acid B protected host cells against EVD68 infection and decreased viral production by intervening in the cell cycle environment that favors viral replication; however, rheum emodin, astragaloside, and artemisinin did not have these effects. Similar to pseudolaric acid B, either oridonin or erianin induced cell cycle arrest in the G2/M phase, also exerting anti-EVD68 effects. These results reinforce our model of EVD68 viral pathogenic mechanisms that require regulation of the cell cycle and suggest that natural compounds affecting the G2/M phase might be potential candidates for the treatment and prevention of EVD68-related diseases.
| MATERIALS AND METHODS

| Materials
The US/KY/14-18953 (American Type Culture Collection [ATCC], VR-1825D) strain of EVD68 was propagated in human rhabdomyosarcoma RD cells , and the supernatants were harvested and stored at −80°C. RD cells were purchased from the ATCC (Manassas, VA, USA). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Grand Island, NY, USA). Rheum emodin, astragaloside, artemisinin, pseudolaric acid B, oridonin, and erianin, which was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution.
DMSO concentration was kept below 0.01% in all the cell cultures, and did not exert any detectable effect on cell growth or cell death.
| Viral titer determination
The viral titers were determined by measuring the 50% tissue culture infective dose (TCID50) in a microtitration assay using RD cells. RD cells were seeded and incubated at 37°C for 24 hr in 96-well plates.
Virus-containing supernatant was serially diluted 10-fold, and 100 μl of diluent virus was added per well in octuplicate. Until the experimental endpoint was reached the cytopathic effect was observed once per day. According to the Reed-Muench method (Reed & Muench, 1983) the viral titers of the TCID50 were determined, based on the assumption that material with 1 × 10 5 TCID50/ml will produce 0.7 × 10 5 plaque forming units per milliliter (www.protocol-online.org/biologyforums/posts/1664.html).
| Infection
Cells were mock-infected or infected with EVD68 at a multiplicity of infection (MOI) of 1. After 2 hr of virus adsorption, cells were washed with phosphate-buffered saline (PBS) one time, and then added fresh culture medium. 
| Cell growth inhibition test
| Cell cycle analysis by flow cytometry
Nuclear DNA content was measured using propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS). Adherent cells were collected by treatment with trypsin and then washed with PBS. Cells were fixed in 1 ml of cold 70% ethanol overnight at 4°C and resuspended in staining buffer (50 μg/ml PI [Sigma] and 20 μg/ml RNase in PBS) for 2 hr at 4°C. The PI-stained cells were then analyzed using FACS (FACScan; BD), and at least 10,000 cells were counted for each sample. Data analysis was performed using ModFit LT, version 2.0 (Verity Software House).
| Virus collection by ultracentrifugation
For analysis of viral protein expression, supernatants were collected and brought up to 5 ml with DMEM. The supernatants were then subjected to repeated freezing and thawing for 3 cycles. Subsequently, the freeze/thawed preparations were centrifuged at 3,000 rpm for 20 min and the pellets were discarded. The medium with virus was then filtered with a 0.22 μm filter. Supernatants containing virus were centrifuged at 30,000 rpm for 3 hr with 30% sucrose using a Type 70.1
Ti rotor in a Beckman ultracentrifuge (Optimal L-100XP ultracentrifuge Beckman Coulter; Song et al., 2018) .
| Western blot analysis
Western blot analysis was performed as previously described . The following mouse or rabbit antibodies were used:
anti-cyclinB1 (Santa Cruz, sc-245, Dilution 1:1000), anti-CDK1 Mouse and rabbit secondary antibodies were obtained from Proteintech (Dilution 1:1000).
| Statistical analyses
Data are presented as the mean ± standard deviation (SD). Betweengroup differences were assessed using Student's t-test, and multiplegroup differences were assessed using post hoc test of one way ANOVA in SPSS 10.0. *p values of less than 0.05 were considered statistically significant. (Figure 1d ), and the IC50 was 10.54 μM. Therefore, the range of concentrations for rheum emodin (0 to 100 μM), artemisinin (0 to 100 μM), astragaloside (0 to 100 μM), and pseudolaric acid B (0 to 1.5 μM) did not affect cell survival. Based on the results of both a published study and our MTT assay, we chose the following concentrations for subsequent experiments: 100 μM rheum emodin, 100 μM artemisinin, 100 μM astragaloside, and 1.5 μM pseudolaric acid B. Figure 1e illustrates the protocol used in the followed experiment.
| Pseudolaric acid B protects host cells from damage induced by EVD68 viral infection
To further exclude the possibility that the antiviral effects of rheum emodin, artemisinin, astragaloside, and pseudolaric acid B were due to their cytotoxic effects, as well as to confirm their protective effects in host cells, first, mock-infected cells were treated with 100 μM rheum emodin, 100 μM artemisinin, 100 μM astragaloside, or 1.5 μM pseudolaric acid B for 22 hr, and no differences in morphology were observed between control and drug-treated cells ( 3.3 | Effects of rheum emodin, artemisinin, astragaloside, and pseudolaric acid B on viral RNA replication and production
To determine whether viral RNA replication and/or transcription was influenced by treatment with these drugs, we used quantitative PCR (qPCR) to assess EVD68 VP1-coding sequence levels at 12 hr of postinfection; EVD68 has a single-stranded, positive-sense RNA genome, so detecting the VP1-coding sequence level is equivalent to detecting levels of the EVD68 genome. EVD68 RNA levels in rheum emodintreated cells (0.78 ± 0.04) were significantly lower than those in the control cells (1.00 ± 0.03, p < 0.01). Treatment with artemisinin (0.86 ± 0.11) did not affect EVD68 levels compared with the control group (1.00 ± 0.14). And astragaloside (0.68 ± 0.11) decreased EVD68 RNA levels compared with control cells (1.00 ± 0.14, p < 0.05). Pseudolaric acid B (0.43 ± 0.03) significantly decreased EVD68 levels compared with control cells (1.00 ± 0.03, p < 0.001; Figure 3a ). Thus, rheum emodin, astragaloside, and pseudolaric acid B all decreased viral RNA levels. To understand the inhibitory effects of these drugs on EVD68 production, the 50% tissue culture infectious dose (TCID50) was examined at 36 hr of postinfection to evaluate the viral virulence. The TCID50/ml was 2.81 × 10 9 in mock-treated cells, 3.39 × 10 9 in rheum emodin-treated cells, 1.66 × 10 9 in artemisinin-treated cells, 2.25 × 10 9 in astragaloside-treated cells, and 1.24 × 10 7 in pseudolaric acid B-treated cells (p < 0.01, Figure 3 b). These results showed that rheum emodin, artemisinin, and astragaloside did not inhibit viral production, whereas pseudolaric acid B had significant inhibitory effects on viral production. In our previous study, we showed that the EVD68 virus induced cell cycle arrest in the G0/G1 phase to promote viral replication . Therefore, we used flow cytometry to examine the Figure 4d ). These findings suggest that pseudolaric acid B inhibits G0/G1 phase cell cycle accumulation induced by EVD68 infection to inhibit viral production.
| Effects of oridonin on viral production
Pseudolaric acid B decreased viral production by inhibiting EVD68-induced accumulation of cells in the G0/G1 phase, possibly because it arrested the cell cycle in the G2/M phase, so we detected the effect of another G2/M-related natural compound on viral production.
Oridonin, an active diterpeniod isolated from R. rubescens, induces cell cycle arrest in the G2/M phase and has been utilized to confirm the effects of G2/M-related drugs on viral production. Concentrations of oridonin resulting in inhibitory ratios below 10% ranged from 0 to 4 μM, and the IC50 was 9.05 μM (Figure 5a ), so a concentration of 4 μM was used in subsequent experiments. Flow cytometry showed that oridonin treatment increased the percentage of cells in the G2/M phase from 25.52% ± 1.42% to 42.65% ± 2.77%
(p < 0.001) compared with the control treatment, and decreased the percentage of cells in the G0/G1 phase from 49.18% ± 0.63% to 38.04% ± 1.95% after EVD68 infection (Figure 5b , p < 0.001). Morphological analysis of the effects of rheum emodin, artemisinin, astragaloside, and PAB on cell growth after EVD68 infection. Mock infection, or infection with EVD68 at an MOI of 1, 22 hr after treatment with 100 μM rheum emodin, 100 μM astragaloside, 100 μM artemisinin, or 1.5 μM PAB B, cell growth was visualized by light microscopy. (c) Nuclear morphological analysis of the effects of rheum emodin, artemisinin, astragaloside, and PAB on cell growth after EVD68 infection. Mock infection, or infection with EVD68 at an MOI of 1, 22 hr after treatment with 100 μM rheum emodin, 100 μM astragaloside, 100 μM artemisinin, or 1.5 μM PAB, cells were stained with Hoechst 33258. Condensed nuclei were observed by fluorescence microscopy. Mock: mock-infected; infected: EVD68-infected; rheu: rheum emodin; arte: artemisinin; astra: astragaloside; PAB: pseudolaric acid B; Con: 0.1% DMSO in 10% DMEM. Bar = 45 μm. The results are representative of three independent experiments [Colour figure can be viewed at wileyonlinelibrary.com]
Morphological analysis showed that oridonin could protect cells from damage induced by EVD68 infection (Figure 5c ). Oridonin treatment also decreased EVD68 RNA levels from 1.00 ± 0.12 to 0.15 ± 0.01 compared with control treatment (p < 0.001; Figure 5d ). Furthermore, oridonin treatment decreased the TCID50/ml from 1.68 × 10 9 to 3.28 × 10 5 compared with control cells (p < 0.01; Figure 5e ). These data show that oridonin inhibited EVD68 viral production by inducing G2/M cell cycle arrest.
| Effects of erianin on viral production
Besides oridonin, we also detected the effect of another G2/Mrelated natural compound erianin ) on viral production. Concentrations of erianin resulting in inhibitory ratios below 10% ranged from 0 to 1 nM, and IC50 was 22.75 nM (Figure 6a ), so a concentration of 1.0 nM was used in subsequent experiments. Flow cytometry showed that erianin treatment increased the percentage of cells in the G2/M phase from 35.23% ± 1.40% to 96.94% ± 1.01% (p < 0.001) compared with the control treatment, and decreased the percentage of cells in the G0/G1 phase from 40.37% ± 1.34% to 0.15% ± 0.25% after EVD68 infection (Figure 6 b, p < 0.001). Morphological analysis showed that erianin could protect cells from damage induced by EVD68 infection (Figure 6c ). Erianin treatment also decreased EVD68 RNA levels from 1.00 ± 0.02 to 0.39 ± 0.09 compared with control treatment (p < 0.01; Figure 6d ).
Furthermore, erianin treatment decreased the TCID50/ml from 2.84 × 10 9 to 2.3 × 10 5 compared with control cells (p < 0.001; Figure 6e ). These data show that erianin inhibited EVD68 viral production by inducing G2/M cell cycle arrest.
| The mechanism of natural compounds related to G2/M phase arrest inhibiting enterovirus D68 production
To confirm the inhibitory effect of natural compounds related to G2/ M phase arrest on viral production, the survival ratio after different drugs treatment was detected by MTT assay in EVD68 infected cells, and the 50% effective concentration (EC50) of pseudolaric acid B, oridonin, and erianin was 1.5 μM, 4 μM, and 1 nM, respectively (Figure 7a ). To investigate the mechanism of natural compounds related to G2/M phase arrest inhibiting enterovirus D68 production, intracellular viral protein expression, supernatant viral protein expression and supernatant viral genome level were detected, and it was found that pseudolaric acid B, oridonin, and erianin had the trend to decrease the intracellular viral protein expression, but there were no significant difference (Figure 7b ). Meanwhile, pseudolaric acid B and erianin had the trend to decrease the supernatant viral protein level, but there were no significant difference, however, oridonin obviously decreased the supernatant vial protein level (Figure 7c ). In addition, pseudolaric acid B, oridonin, and erianin significantly decreased At 10 hr of posttreatment with 100 μM rheum emodin, 100 μM artemisinin, 100 μM astragaloside, or 1.5 μM PAB, the VP1-coding sequence was detected. The results were standardized using GAPDH RNA as a control and normalized to 1 in control cells. The results indicate the mean ± SD of three independent experiments. NS: no significant difference, *p < 0.05, **p < 0.01, and ***p < 0.001. (b) At 36 hr of postinfection, the total progeny virus (supernatant and intracellular viruses) was titrated using RD cells, and the TCID50/ml value was determined. The results represent the mean ± SD of three independent experiments. NS: no significant difference, **p < 0.01. Rheu: rheum emodin; arte: artemisinin; astra: astragaloside; PAB: pseudolaric acid B; Con: 0.1% DMSO in 10% DMEM supernatant viral genome level from 100 ± 23.84 to 8.84 ± 7.60, from 100 ± 23.84 to 1.85 ± 1.22 and from 100 ± 23.84 to 0.92 ± 1.52, respectively ( Figure 7d ). Therefore, natural compounds related to G2/M phase arrest inhibiting enterovirus D68 production is related to the multiple-step during viral production.
Followed that, we also detected the effect of pretreatment of G2/ M-related natural compound on viral production. RD cells were 1.75× 10 6 , and 8.27 × 10 9 to 0.50× 10 6 , respectively (Figure 8d , p < 0.001). Therefore, these data show that pretreatment of G2/Mrelated natural compound also inhibited EVD68 viral production.
Meanwhile, it was found that pseudolaric acid B, oridonin, and erianin treatment increased the expression of cyclinB1, which is related to G2/M arrest compared with control treatment, but EVD68
infection decreased the expression of cyclinB1 compared with mock infection after pseudolaric acid B, oridonin, and erianin treatment (Figure 9 ), therefore, it was speculated that for viral production, EVD68 began to interfere host cyclinB1 expression, leading that inhibited the final step in viral maturation. In addition, rheum emodin, astragaloside, and artemisinin did not affect viral production compared with the control group, which explains why they did not have protective effects against EVD68 infection. Although rheum emodin and astragaloside decreased RNA levels compared with the controltreated group, they ultimately could not decrease viral production. It appears that the key step for viral production is not at the genomic level but occurs after genome replication instead.
In our previous study , we showed that EVD68-induced cell cycle arrest in the G0/G1 phase to facilitate viral production. However, pseudolaric acid B decreased the amount of cells in G0/G1 phase induced by EVD68, resulting in an increased ratio of cells in the G2/M phase compared with control-treated cells.
Therefore, we conclude that pseudolaric acid B inhibits EVD68 viral production by inducing G2/M arrest to decrease G0/G1 accumulation favored by EVD68 production, which is a very important point for directing anti-EVD68 drug development. Hence, to further confirm the role of G2/M-related compounds in viral production, oridonin and erianin were used and shown to significantly decrease RNA levels and viral production compared with control treatment, and the results are similar to pseudolaric acid B. These results confirm that G2/Mrelated compounds can inhibit viral production. Rheum emodin, artemisinin, and astragaloside did not decrease the percentage of cells in the G0/G1 phase upon EVD68 infection, showing that they do not have protective effects against this virus. Therefore, it appears that G2/M phase-related drugs can inhibit EVD68 production.
Then, it was investigated that G2/M phase-related drugs inhibited EVD68 production, it was found that pseudolaric acid B Wang et al., 2018) , oridonin (Zheng et al., 2017) , and erianin did not affect intracellar viral protein expression although they had the trend to decrease the expression, therefore, it was speculated that the decreased trend was due to decreased viral mRNA level by pseudolaric acid B, oridonin, and erianin, respectively.
Meanwhile, only oridonin affected supernatant viral protein expression, but all of them decreased supernatant viral genome level, and virions partly explained the decreased production. In addition, it was found that treatment of pseudolaric acid, oridonin, and erianin before viral infection also inhibited viral production, and the inhibiting ability with this kind of treatment was same as treatment after viral infection, further proving that G2/M phase-related drugs might affect viral maturation. Importantly, it was noted that nocodozole, which induced G2/ M arrest inhibited EV71 production, therefore, in enterovirus treatment, G2/M phase-related drugs might be optimal. At the same time, it was found that pseudolaric acid, oridonin, and erianin increased the expression of cyclinB1, respectively, but EVD68 inhibited the increase of cyclinB1, therefore, it was speculated that EVD68 focused on regulating cyclinB1 expression, but lost the chance to proliferate. Meanwhile, it was found that EVD68 infection increased the expression of P53, P27 and P21 compared to mock-infected group, while pseudolaric acid, oridonin and erianin treatment decreased their expressions in EVD68-infected cells compared to control treatment, indicating that pseudolaric acid B, oridonin, and erianin disrupted the cell cycle status-manipulated by EVD68 through regulating cell cycle-related protein expression.
It is worth noting that pseudolaric acid B, oridonin, and erianin were extracted from P. kaempferi Grord (Pinaceae; Yu et al., 2007; Yu et al., 2013; Yu et al., 2016; Yu et al., 2017; Yu, Wang, et al., 2008) , R. rubescens Ye et al., 2012) and Dendrobium chrysotoxum , respectively, which should be considered for treating EVD68-related diseases. However, rheum emodin, artemisinin, and astragaloside were extracted from Chinese rhubarb (also from Polygonum cuspidatum Sieb.et Zucc, Rumex patientia Linn, Fagopyrum dibotrys (D.Don) Hara, Rumex japonicus Houtt, Fallopia multiflora (Thunb.)
Harald), Artemisia carvifolia, and Astragalus, respectively (Pang, Liu, Li, Zhao, & Zhang, 2015; Yeung et al., 2004; Chen et al., 2011) , thus, on the basis of the results of our study, these Chinese herbs should not be used to treat EVD68-related diseases.
The results of this study contribute to our understanding of the viral pathogenic mechanisms of EVD68 and demonstrate that G2/Mrelated natural compounds might be potential candidates for the treatment and prevention of EVD68-related diseases, and Chinese herbs (c) VP1 expression in viral supernatants was determined after growth in control medium or PAB, oridonin, or erianin medium at 24 hr of postinfection. The numerical value shown is the ratio of VP1 protein intensity in control medium to the intensity in the drug treatment group. The results are representative of three independent experiments. (D) At 36 hr of postinfection, the total progeny viruses (the supernatant and intracellular viruses) were titrated using RD cells, and the TCID50/ml value was determined. The results represent the mean ± SD of three independent experiments. **p < 0.01. Eri: erianin; Mock: mock-infected; EVD: EVD68 infected; Con: 0.1% DMSO in 10% DMEM
FIGURE 9
The expression of cell cycle related proteins was detected after PAB, oridonin, and erianin treatment. Intracellular cyclinB1, CDK1, P53, P27, and P21 expression was determined after growth in control medium or PAB, oridonin, or erianin medium at 24 hr of postinfection.
Histone is shown as a loading control. The results are representative of three independent experiments. PAB: pseudolaric acid B, Ori: oridonin, Eri: erianin, Con: control, infected: EVD68 infection, Mock: mock infection with those natural compounds should be used in the clinic and be planted on a large scale in agriculture. This study provides a new direction for anti-virus drug development from the point of host cell cycle.
